Veru announces presentation of preclinical evidence supporting the therapeutic benefit of enobosarm alone or in synergistic combination with a cdk4/6 inhibitor against palbociclib resistant metastatic breast cancer at the 2021 san antonio breast cancer symposium

Miami, dec. 08, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating that enobosarm treatment alone as well as in combination with a cdk4/6 inhibitor increased androgen receptor (ar) expression resulting in the synergistic suppression of breast cancer cell and tumor models that are resistant to cdk4/6 inhibitors and estrogen blocking agents. enobosarm is an oral, first-in-class, selective androgen receptor targeted agonist for the androgen receptor, a tumor suppressor, being evaluated in phase 3 clinical studies to treat ar+er+her2- metastatic breast cancer without unwanted masculinizing side effects. the presentation was selected as a spotlight presentation at the san antonio breast cancer symposium being held december 07-10, 2021, in san antonio, tx.
VERU Ratings Summary
VERU Quant Ranking